Products for Research Use Only
RegisterLogin

Tumor biomarker research

Cancer Marker Antibodies for Tumor Detection and Characterization Research

Cancer marker antibodies recognize proteins associated with tumor cells, particular cellular lineages, proliferation, differentiation, signaling pathways or the tumor microenvironment. Researchers use them to examine biomarker expression in tissues, cultured cells, lysates and other experimental samples. Compare products by molecular target, clone, host species, species reactivity, clonality, conjugation, validated application, staining pattern, format and pack size.

Browse productsSelection guideFAQs

Product catalog

Browse Cancer Marker Antibodies

Compare product names, catalog numbers, available sizes, pricing, and product specifications.

What are cancer marker antibodies?

Cancer marker antibodies bind proteins studied in relation to tumor development, cell identity, proliferation, differentiation, invasion, immune regulation or treatment response. These targets may include receptors, transcription factors, structural proteins, enzymes and cell-surface molecules. A cancer-associated marker is not necessarily found only in malignant cells, so its biological context and expression in normal tissues should also be considered.

Researchers use these antibodies to examine where a biomarker is expressed, which cells express it and how its abundance changes between samples or experimental conditions. Depending on the individual antibody, relevant methods may include immunohistochemistry, immunofluorescence, Western blotting, flow cytometry, immunoprecipitation and plate-based assays. No single method provides every type of information about a marker.

Reliable biomarker research requires an antibody validated for the intended sample and method, together with appropriate positive and negative controls. Fixation, antigen retrieval, tissue processing, target abundance and scoring criteria can substantially affect results. Antibody staining alone should not be interpreted as proof of malignancy, clinical diagnosis or eligibility for treatment unless it forms part of an appropriately validated diagnostic procedure.

Buying and selection guide

How to choose a cancer marker antibody

Begin with the biological question rather than the marker name alone. Define the target, sample, method and expected expression pattern before comparing available clones and formats.

01

Define the biological purpose

Determine whether the marker will be used to study cell identity, proliferation, signaling, immune response, differentiation or another tumor-related process.

02

Confirm sample compatibility

Check species reactivity and whether the antibody supports fixed tissue, frozen tissue, cultured cells, lysates or the other sample format used in the experiment.

03

Match the validated application

Choose an antibody tested for the intended method because performance in Western blotting does not automatically establish suitability for tissue staining or flow cytometry.

04

Review clone and epitope information

Compare clone, clonality, immunogen and recognized region where available, particularly when fixation, isoforms, cleavage or post-translational modification may affect recognition.

05

Plan expression controls

Use known positive and negative samples, reagent controls and method-specific controls to verify staining performance and distinguish target signal from background.

06

Check the intended-use status

Confirm whether the antibody is supplied for research use or as part of a validated diagnostic system. A research antibody should not be treated as a clinical test.

Frequently asked questions about cancer marker antibodies

These questions cover common selection, validation and interpretation issues encountered when studying tumor-associated proteins with antibodies.

What is a cancer marker antibody?

A cancer marker antibody recognizes a protein investigated in relation to tumors, malignant cells or the tumor microenvironment. The target may provide information about cellular identity, proliferation, signaling, differentiation or immune activity. However, many cancer-associated markers are also expressed by normal or benign tissues, so results must be interpreted in the correct biological context.

Are cancer markers found only in cancer cells?

Not usually. Many markers studied in cancer are normal proteins whose abundance, location or activation state changes in particular tumors. Some are also expressed in healthy tissue, inflammatory conditions or benign disease. Researchers should review the expected normal expression pattern and include suitable comparison samples before describing a signal as tumor-specific.

How do I choose the right antibody for a cancer biomarker?

Confirm the exact molecular target, species, sample type and experimental method first. Then compare clone, clonality, recognized epitope, conjugation and available validation data. For tissue studies, also consider fixation and antigen-retrieval conditions. The best choice is an antibody supported for conditions that closely resemble the planned experiment.

Can the same cancer marker antibody be used for immunohistochemistry and Western blotting?

Only when the individual antibody has been validated for both applications. Western blotting generally detects a denatured protein separated by molecular weight, whereas immunohistochemistry detects an antigen within processed tissue. Fixation and antigen retrieval may expose or conceal different epitopes, causing the same clone to perform differently between methods.

Why am I seeing high background in cancer marker staining?

High background may result from excessive antibody concentration, insufficient blocking, endogenous enzyme activity, tissue autofluorescence, inappropriate secondary antibodies or incomplete washing. Necrotic tissue and highly charged sample components can also produce nonspecific signal. Titrating the primary antibody and reviewing each detection step can help identify the source.

Which controls should I use for cancer marker antibody experiments?

Include a sample known to express the target and a sample expected to lack or minimally express it. Depending on the method, additional controls may include no-primary, secondary-only, isotype, unstained and single-color controls. Controls should verify both antibody performance and the specificity of the complete detection workflow.

Does tissue fixation affect cancer marker antibody detection?

Yes. Fixation duration, fixative type, tissue thickness, processing and storage can alter antigen structure or accessibility. Under-fixation may damage morphology, while prolonged fixation may mask epitopes. Antigen retrieval can restore some epitopes, but the appropriate conditions depend on the target, antibody clone and tissue preparation method.

Can a research-use cancer marker antibody be used for clinical diagnosis?

A research-use antibody should not automatically be used or interpreted as a clinical diagnostic test. Diagnostic immunohistochemistry requires an appropriately validated assay, controlled procedures and interpretation within the applicable laboratory and regulatory framework. Product documentation should be checked carefully to determine the antibody's stated intended use.

Related Antibodies categories

Affinity Tag AntibodiesBiosimilar AntibodiesConjugated AntibodiesFlow Cytometry AntibodiesImmunology AntibodiesInfectious Disease AntibodiesIsotype Control AntibodiesMonoclonal AntibodiesNeuroscience AntibodiesPhosphorylated Antibodies